ABBV congressional trades
AbbVie Inc. (ABBV) appears in 37 congressional disclosure rows from 14 members of Congress in 2025–2026 periodic reports: 20 purchases and 17 sales, with trade dates from Sep 26, 2024 to Sep 14, 2026. Lisa McClain reported the most, with 6 rows. The median gap between trade date and filing date is 28 days, and 6 trades were reported more than 45 days after it happened.
Rows keep the disclosed owner and amount range. This is a record of reported transactions, not a live ABBV portfolio or a trading signal.
- 37
- 14
- 20 / 17
- $163K – $795K
- sum of reported ranges
- 2026-09-14
Verified ABBV congressional disclosures
Parsed from official House Clerk and Senate eFD filings. This snapshot contains 20 purchases and 17 sales. Reported owners: Self, Joint, Spouse, Dependent. Transaction dates run from 2024-09-26 to 2026-09-14.
| Politician | Trade date | Asset | Type | Owner | Amount | Filing |
|---|---|---|---|---|---|---|
| Pete Sessions | AbbVie Inc. Common Stock | Sale | Self | $15,001 - $50,000 | #20035480 Filed 2026-09-18 | |
| Josh Gottheimer | AbbVie Inc. Common Stock | Sale | Joint | $1,001 - $15,000 | #20034693 Filed 2026-06-03 | |
| Alan Armstrong | AbbVie Inc. Common Stock | Purchase | Self | $15,001 - $50,000 | #fda235b3-bad7-4637-8fa1-053f354d929c Filed 2026-07-21 | |
| Julie Johnson | AbbVie Inc. Common Stock | Sale | Joint | $1,001 - $15,000 | #20033789 Filed 2026-01-15 | |
| Julia Letlow | AbbVie Inc. Common Stock | Sale | Self | $1,001 - $15,000 | #20030977 Filed 2026-01-13 | |
| Julie Johnson | AbbVie Inc. Common Stock | Sale | Joint | $1,001 - $15,000 | #20033611 Filed 2025-12-11 | |
| Lisa McClain | AbbVie Inc. Common Stock | Sale | Spouse | $1,001 - $15,000 | #20033446 Filed 2025-11-21 | |
| Lisa McClain | AbbVie Inc. Common Stock | Sale | Spouse | $1,001 - $15,000 | #20033446 Filed 2025-11-21 | |
| Lisa McClain | AbbVie Inc. Common Stock | Purchase | Spouse | $1,001 - $15,000 | #20033446 Filed 2025-11-21 | |
| John Boozman | Abbvie Inc | Sale | Joint | $1,001 - $15,000 | #c104f1ee-c957-4485-9807-e4798463c3b9 Filed 2025-09-12 | |
| Julie Johnson | AbbVie Inc. Common Stock | Sale | Joint | $1,001 - $15,000 | #20032066 Filed 2025-09-11 | |
| John Boozman | Abbvie Inc | Sale | Joint | $1,001 - $15,000 | #c104f1ee-c957-4485-9807-e4798463c3b9 Filed 2025-09-12 | |
| Marjorie Greene | AbbVie Inc. Common Stock | Purchase | Self | $1,001 - $15,000 | #20030924 Filed 2025-08-15 | |
| Lisa McClain | AbbVie Inc. Common Stock | Sale | Spouse | $1,001 - $15,000 | #20030891 Filed 2025-08-13 | |
| Lisa McClain | AbbVie Inc. Common Stock | Purchase | Spouse | $1,001 - $15,000 | #20030891 Filed 2025-08-13 | |
| Ritchie Torres | AbbVie Inc. Common Stock | Sale | Self | $1,001 - $15,000 | #20030930 Filed 2025-08-20 | |
| Lisa McClain | AbbVie Inc. Common Stock | Purchase | Spouse | $1,001 - $15,000 | #20030891 Filed 2025-08-13 | |
| Josh Gottheimer | AbbVie Inc. Common Stock | Purchase | Joint | $1,001 - $15,000 | #20030462 Filed 2025-06-11 | |
| Robert Bresnahan | AbbVie Inc. Common Stock | Purchase | Self | $1,001 - $15,000 | #20030482 Filed 2025-06-09 | |
| Marjorie Greene | AbbVie Inc. Common Stock | Purchase | Self | $1,001 - $15,000 | #20030295 Filed 2025-05-06 | |
| Julia Letlow | AbbVie Inc. Common Stock | Purchase | Self | $1,001 - $15,000 | #20030977 Filed 2026-01-13 | |
| Josh Gottheimer | AbbVie Inc. Common Stock | Sale | Joint | $1,001 - $15,000 | #20030338 Filed 2025-05-14 | |
| Jefferson Shreve | AbbVie Inc. Common Stock | Sale | Self | $50,001 - $100,000 | #20030231 Filed 2025-05-08 | |
| Robert Bresnahan | AbbVie Inc. Common Stock | Sale | Self | $1,001 - $15,000 | #20030291 Filed 2025-05-08 | |
| Jared Moskowitz | AbbVie Inc. Common Stock | Purchase | Self | $1,001 - $15,000 | #20030282 Filed 2025-05-09 | |
| Josh Gottheimer | AbbVie Inc. Common Stock | Purchase | Joint | $1,001 - $15,000 | #20030338 Filed 2025-05-14 | |
| Dwight Evans | AbbVie Inc. Common Stock | Sale | Self | $1,001 - $15,000 | #20030179 Filed 2025-04-17 | |
| Josh Gottheimer | AbbVie Inc. Common Stock | Purchase | Joint | $1,001 - $15,000 | #20030338 Filed 2025-05-14 | |
| Marjorie Greene | AbbVie Inc. Common Stock | Purchase | Self | $1,001 - $15,000 | #20028002 Filed 2025-03-19 | |
| Robert Bresnahan | AbbVie Inc. Common Stock | Purchase | Self | $1,001 - $15,000 | #20029034 Filed 2025-03-27 | |
| Jefferson Shreve | AbbVie Inc. Common Stock | Purchase | Self | $50,001 - $100,000 | #20027879 Filed 2025-03-09 | |
| Julia Letlow | AbbVie Inc. Common Stock | Sale | Self | $1,001 - $15,000 | #20030977 Filed 2026-01-13 | |
| Jared Moskowitz | AbbVie Inc. Common Stock | Purchase | Dependent | $1,001 - $15,000 | #20026731 Filed 2025-02-10 | |
| Jared Moskowitz | AbbVie Inc. Common Stock | Purchase | Self | $1,001 - $15,000 | #20026731 Filed 2025-02-10 | |
| Virginia Foxx | AbbVie Inc. Common Stock | Purchase | Self | $1,001 - $15,000 | #20026516 Filed 2025-01-06 | |
| Julia Letlow | AbbVie Inc. Common Stock | Purchase | Self | $1,001 - $15,000 | #20030977 Filed 2026-01-13 | |
| Ritchie Torres | AbbVie Inc. Common Stock | Purchase | Self | $1,001 - $15,000 | #20030930 Filed 2025-08-20 |
A filing can describe the member, a spouse, a dependent, or a joint asset. Amounts are statutory ranges, not execution prices. See how to read congressional stock-trade disclosures before treating a delayed row as a trading signal.
ABBV disclosures by member
| Member | Rows | Buys | Sells | Last trade |
|---|---|---|---|---|
| Lisa McClain's ABBV trades | 6 | 3 | 3 | 2025-10-31 |
| Josh Gottheimer's ABBV trades | 5 | 3 | 2 | 2026-05-05 |
| Julia Letlow's ABBV trades | 4 | 2 | 2 | 2025-12-08 |
| Jared Moskowitz's ABBV trades | 3 | 3 | 0 | 2025-04-07 |
| Julie Johnson's ABBV trades | 3 | 0 | 3 | 2025-12-18 |
| Marjorie Greene's ABBV trades | 3 | 3 | 0 | 2025-08-04 |
| Robert Bresnahan's ABBV trades | 3 | 2 | 1 | 2025-05-15 |
| Jefferson Shreve | 2 | 1 | 1 | 2025-04-17 |
| John Boozman | 2 | 0 | 2 | 2025-08-22 |
| Ritchie Torres | 2 | 1 | 1 | 2025-07-11 |
| Alan Armstrong | 1 | 1 | 0 | 2026-03-27 |
| Dwight Evans | 1 | 0 | 1 | 2025-04-03 |
| Pete Sessions | 1 | 0 | 1 | 2026-09-14 |
| Virginia Foxx | 1 | 1 | 0 | 2024-12-06 |
How long disclosure took
Days from trade date to filing date for 37 rows. The STOCK Act allows 30 days from notification and no more than 45 days from the trade. A late row is a timing fact, not evidence of wrongdoing.
- 0–15 days
- 6
- 16–30 days
- 18
- 31–45 days
- 7
- Over 45 days
- 6
- Median / longest
- 28d / 447d
Source documents
25 House Clerk and Senate eFD periodic transaction reports, newest first. Each link opens the official filing.
- #20035480Filed 2026-09-18 · 1 row
- #fda235b3-bad7-4637-8fa1-053f354d929cFiled 2026-07-21 · 1 row
- #20034693Filed 2026-06-03 · 1 row
- #20033789Filed 2026-01-15 · 1 row
- #20030977Filed 2026-01-13 · 4 rows
- #20033611Filed 2025-12-11 · 1 row
- #20033446Filed 2025-11-21 · 3 rows
- #c104f1ee-c957-4485-9807-e4798463c3b9Filed 2025-09-12 · 2 rows
- #20032066Filed 2025-09-11 · 1 row
- #20030930Filed 2025-08-20 · 2 rows
- #20030924Filed 2025-08-15 · 1 row
- #20030891Filed 2025-08-13 · 3 rows
13 older filings are linked from the transaction table.
What ABBV filings don’t tell you
A disclosure row records a trade date, an amount bracket, and who owned the asset. It does not say why the trade was made, whether the position is still held, or anything about the business behind the ticker: revenue trends, margins, balance-sheet risk, or valuation. Those answers are in company filings, not congressional ones.
- AbbVie Inc. financials and filings
Audited SEC figures, what moves ABBV, and primary sources.
Compare ABBV vs LLY side by side
To work through a company yourself, use our stock research checklist. Members get the full version of that work: one sourced investment call a month, with the numbers and the risks that would change the view.
Members-only research
What members are reading this month
- NVIDIA’s growth has a financing bill
Sales up about 18% on the prior quarter, receivables up about 55%, supply commitments at $279 billion. What NVIDIA’s financing bill means for the price you pay.
- Citadel bought the AI fire sale. The seller had run out of time.
Up 439% in the first half, down about 67% in July: how an AI hedge fund ended up selling a roughly $16 billion stock book to Citadel at a discount.
The thesis, the numbers behind it, and what would break it. Full access is $39 a month.
Read the full researchRelated research
ABBV congressional trades: FAQ
Who in Congress traded ABBV?
House Clerk and Senate eFD periodic reports for 2025 and 2026 contain 37 verified ABBV rows from 14 members: Alan Armstrong, Dwight Evans, Jared Moskowitz, Jefferson Shreve, and 10 other members. Image-only filings are excluded, and this is not a live brokerage statement.
Does this page show current ABBV holdings?
No. STOCK Act filings disclose reportable transactions after the fact, usually within 45 days, as amount ranges and owners. They do not prove a current position, an exact share count, or why the trade happened.
Why are ABBV amounts shown as ranges?
Congressional periodic transaction reports use statutory value bands such as $15,001 - $50,000; $1,001 - $15,000; $50,001 - $100,000. Yield Theory keeps those ranges instead of inventing a midpoint, exact trade size, or return.
How complete is ABBV congressional-trade coverage?
This snapshot covers every machine-readable House and Senate periodic transaction report for 2025 and 2026 (178 members). Image-only House filings and paper Senate filings are not included, so missing rows are not proof that no other lawmaker traded ABBV.
Yield Theory is not affiliated with any elected official. This page uses the 2025–2026 House Clerk and Senate eFD periodic report snapshot generated 2026-11-03. It is not a complete lifetime portfolio, a performance track record, or investment advice.
A disclosure is not a thesis.
This page shows who reported ABBV and in what range. Membership is the monthly sourced call, plus a five-minute check when the evidence moves. $39/month or $249/year.
Members-only research
$39/mo or $249/yr · cancel future renewals anytime · sources included